View Older Stories View More Recent Stories

Jun 27, 2023 05:15PM MEI Pharma Responds to Anson and Cable Car
Jun 15, 2023 12:08PM MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
Jun 15, 2023 08:00AM MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
Jun 13, 2023 08:00AM MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor
Jun 2, 2023 08:01AM MEI Pharma (MEIP) Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor
Jun 2, 2023 08:00AM MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor
Jun 1, 2023 08:00AM MEI Pharma (MEIP) Rejects Unsolicited $8/sh Proposal
Jun 1, 2023 08:00AM MEI Pharma Board of Directors Rejects Unsolicited Proposal
May 30, 2023 05:43PM MEI Pharma (MEIP) confirms $8/share unsolicited and non-binding takeover proposal from Anson Advisors
May 30, 2023 05:40PM MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal
May 23, 2023 08:00AM MEI Pharma (MEIP) Announces Update of Ongoing Phase 1 Study Evaluating Voruciclib
May 23, 2023 08:00AM MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies
May 11, 2023 04:05PM MEI Pharma Reports Third Quarter Fiscal Year 2023 Results and Operational Highlights
Apr 14, 2023 04:15PM MEI Pharma Announces 1-for-20 Reverse Stock Split
Feb 23, 2023 07:05AM MEI Pharma (MEIP) and Infinity Pharmaceuticals (INFI) Announce Merger Agreement
Feb 23, 2023 07:00AM MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates
Feb 9, 2023 04:05PM MEI Pharma Reports Second Quarter Fiscal Year 2023 Results and Operational Highlights
Dec 6, 2022 04:00PM MEI Pharma Announces Adjournment of Annual Meeting of Stockholders
Dec 5, 2022 05:03PM MEI Pharma (MEIP) and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
Dec 5, 2022 05:02PM MEI Pharma (MEIP) Initiates Strategic Realignment
Dec 5, 2022 05:01PM MEI Pharma Initiates Strategic Realignment
Dec 5, 2022 05:00PM MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
Nov 18, 2022 08:01AM Kyowa Kirin and MEI Pharma (MEIP) Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in Japan
Nov 18, 2022 08:00AM Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in Japan
Nov 14, 2022 04:05PM MEI Pharma Reports First Quarter Fiscal Year 2023 Results and Operational Highlights
Nov 3, 2022 09:00AM MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022
Oct 3, 2022 04:00PM MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Sep 22, 2022 08:02AM MEI Pharma (MEIP) Appoints Christine A. White to its Board
Sep 22, 2022 08:00AM MEI Pharma Announces Changes to Board of Directors
Sep 8, 2022 04:05PM MEI Pharma Reports Fiscal Year 2022 Results and Operational Highlights
Sep 6, 2022 08:00AM MEI Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022
Sep 1, 2022 04:00PM MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Sep 1, 2022 08:00AM MEI Pharma to Release 2022 Fiscal Year End Financial Results and Provide Corporate Update on September 8, 2022
Aug 1, 2022 04:00PM MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Jul 18, 2022 08:00AM MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy
Jul 1, 2022 04:00PM MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Jun 22, 2022 08:00AM MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer
Jun 10, 2022 05:33AM MEI Pharma (MEIP) and Kyowa Kirin Report Clinical Data on Zandelisib
Jun 10, 2022 03:00AM MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress
Jun 6, 2022 05:51AM MEI Pharma (MEIP) and Kyowa Kirin Report Additional Zandelisib Data
Jun 4, 2022 04:00PM MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022
Jun 1, 2022 04:00PM MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 26, 2022 05:00PM MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022
May 23, 2022 04:22PM MEI Pharma (MEIP) Reports Q3 Net Loss $21.5M
May 23, 2022 04:20PM  MEI Pharma Reports Third Quarter Fiscal Year 2022 Results and Operational Highlights
May 17, 2022 08:00AM MEI Pharma to Present at the H.C. Wainwright Global Investment Conference 2022
May 12, 2022 10:00AM MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Association 2022 Hybrid Congress
May 2, 2022 04:00PM MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Apr 8, 2022 01:00PM MEI Pharma Announces Two Presentations at the American Association for Cancer Research Annual Meeting 2022
Apr 1, 2022 04:01PM MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
View More Recent Stories View Older Stories